State Street Corp Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

State Street Corp raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 5.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,014,012 shares of the company’s stock after purchasing an additional 110,162 shares during the period. State Street Corp owned about 4.36% of Pacira BioSciences worth $30,311,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Centiva Capital LP acquired a new position in shares of Pacira BioSciences in the third quarter valued at approximately $398,000. PDT Partners LLC purchased a new stake in Pacira BioSciences in the 3rd quarter worth approximately $3,469,000. Verition Fund Management LLC acquired a new position in Pacira BioSciences in the 3rd quarter valued at $493,000. FORA Capital LLC purchased a new position in shares of Pacira BioSciences during the 3rd quarter worth $431,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Pacira BioSciences by 269.7% during the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after purchasing an additional 288,662 shares during the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Price Performance

Pacira BioSciences stock opened at $18.98 on Friday. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $876.36 million, a P/E ratio of -9.35 and a beta of 0.80. The firm has a fifty day moving average of $17.64 and a 200-day moving average of $18.66. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $35.95.

Analyst Ratings Changes

Several research firms recently commented on PCRX. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a research note on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Royal Bank of Canada raised their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Jefferies Financial Group boosted their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Finally, Barclays cut their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.50.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.